AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04376827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard-of-care treatment
Description: Participants will receive standard of care treatment including MMF/MPA and glucocorticoids from Week 12 through Week 48.
Study NCT04243395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pork
Description: 1 oz lean pork
Study NCT04243395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg
Description: 1 large whole egg
Study NCT04243395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black beans
Description: 0.5 cups cooked black beans
Study NCT04243395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almonds
Description: 0.5 oz almonds
Study NCT02514668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study NCT02899923 — intervention group
Intervention type: OTHER
Intervention: Data collection
Study NCT00408590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: carcinoembryonic antigen-expressing measles virus
Study NCT00408590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oncolytic measles virus encoding thyroidal sodium iodide symporter
Study NCT00408590 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Study NCT00408590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT03633669 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fecal calprotectin
Description: Testing every 3 months
Study NCT03633669 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine care
Description: As per treating gastroenterologist
Study NCT01516567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab
Description: 6 courses of Dose Adjusted-EPOCH-Rituximab Rituximab 375 mg/m² i.v.: one injection at each of the 6 courses of EPOCH.
Study NCT02535416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520
Study NCT02535416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetirizine
Study NCT02535416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine
Study NCT04326764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat should be taken orally once on each scheduled day at about the same time, either with or without food. Each dose of panobinostat should be taken with a cup of water.~The capsules should be swallowed as whole. If vomiting occurs during the course of treatment, no re-dosing is allowed before the next scheduled dose. If one dose is forgotten during the morning on a scheduled treatment day then the missed dose should be taken on that same day within 12 hours. After more than 12 hours, that day's dose should be withheld, and the patient should wait to take panobinostat until the next schedule treatment day. The patient should then continue treatment with the original dosing schedule.~Panobinostat will be administered at a dose of 20 mg three times weekly (TIW) every second week and will be dosed on a flat scale of mg/day and not by weight or body surface area.~Panobinostat will be dispensed as a 20 mg capsule or as two 10 mg capsules.
Study NCT02920957 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: contact lens
Study NCT02920957 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon C
Description: contact lens
Study NCT00272116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc and vitamin A single dose at enrollment
Description: 10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children
Study NCT00272116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and vitamin A single dose at enrollment
Description: Placebo was plain glucose. Vitamin A 100,000 IU to infants and 200,000 IU to older children
Study NCT00721721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Sodium Diet
Description: 3 grams of salt or 51.3 mmol of sodium per day
Study NCT00721721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Sodium Diet
Description: 18 grams of salt or 307.8 mmol of sodium per day
Study NCT00721721 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium Supplementation
Description: 60 mmol potassium supplement
Study NCT01359462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolvaptan
Description: Drug: tolvaptan~tablet, 15mg, Qd, for 7 days.
Study NCT05173935 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous endoscopic gastrostomy
Description: Gastrostomy tube placement using an endoscopic camera inserted via the mouth into the stomach to place the tube.
Study NCT05173935 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiologically-inserted gastrostomy
Description: Gastrostomy tube placement using a temporary nasogastric tube placed from nose to stomach and fluoroscopy (x-rays).
Study NCT02431390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RAPAELⓇ Smart Glove digital treatment system
Description: The RAPAELⓇ Smart Glove digital treatment system is constituted for stroke rehabilitation. For use, stroke patients wear the gloves and play the games or puzzle for rehabilitation of upper limbs. The system provides biofeedback to user.
Study NCT02431390 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Additional occupational therapy
Description: 30 minutes of additional conventional occupational therapy session composed of hand dexteriy training
Study NCT03753100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual-energy X-ray absorbtiometry to evaluate periprosthetic bone mineral density around an uncemented stem implanted using either lateral or anterolateral approach to the hip joint
Description: The measurement will start in the area about 2 cm proximal to the greater trochanter and will stop slightly below the tip of the prosthesis. This is the baseline scan and will be carried out twice with the patient lying on the table, but with movement between each scan. This is done to calculate the CV, Coefficient of Variation. We will use the formula from Wilkinson and associates, where delta is standard deviations (SD) of the difference between the two BMD measurements for each patient. BMD has been measured at baseline, 3 and 12 months. A DXA scan is now planned at 60 months. Changes in BMD related to the 7 Gruen zones will be registered.
Study NCT03814655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full digital workflow
Description: Dental implants will be inserted usig a surgical guide performed after prosthetically driven treatment planning. The workflow will be full digital.
Study NCT03814655 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partially digital workflow
Description: Dental implants will be inserted usig a surgical guide performed after prosthetically driven treatment planning. The workflow will be partially digital.
Study NCT02687347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral methadone
Description: Oral methadone is the study drug
Study NCT00075582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00075582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00075582 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study NCT02154581 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SLActive implant
Study NCT06241079 — intervention group
Intervention type: OTHER
Intervention: non-intervention
Description: non-intervention
Study NCT03194555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-Dose Naltrexone and Acetaminophen Combination
Description: Twice daily
Study NCT03194555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily
Study NCT00642239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
Study NCT00642239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Glycididazole
Description: Sodium Glycididazole 700mg/m2 in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
Study NCT00532584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone
Description: The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
Study NCT02535845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Voice
Description: Project Voice tablet-based intervention plus informational video
Study NCT02535845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV Informational Video
Description: Informational video only
Study NCT02254928 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Corifollitropin alfa
Description: One dose of 150 μg of corifollitropin alfa will be administered at day 1 of stimulation. Stimulation will be continued with 250-300 IU/day of rFSH from day 8 forward.
Study NCT02045797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 Lyophile
Description: GSK2140944 Lyophile (pale yellow to grayish yellow cake) containing 750 mg of GSK2140944 (as free base) per vial for IV infusion.
Study NCT02045797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 Capsules
Description: GSK2140944 500 mg capsules will be supplied as pink hard gelatin capsule with no external markings filled with slightly agglomerated pale yellow to grayish yellow powder.
Study NCT01750099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Spinal-epidural
Description: See arm description
Study NCT01750099 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Lumbar epidural
Description: See arm description
Study NCT01801644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine plus cisplatin
Description: gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion followed by cisplatin 70 mg/m2 on day 1 as an 2 hour infusion
Study NCT04178187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caps Lactolevure
Description: One group will receive Caps Lactolevure x2 and the other group Caps Placebo x2.
Study NCT04178187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caps Placebo
Description: Caps Placebo
Study NCT00832585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: Alefacept 15mg IM every week for 12 weeks
Study NCT02360592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: In arm 1, Entecavir is used for 48 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir is used for 8 weeks.
Study NCT02360592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: In arm 1, Entecavir is used for 48 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir is used for 8 weeks.
Study NCT02360592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Description: In arm 2 and 3, interferon alfa-2b is used for 48 weeks
Study NCT02360592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin 2
Description: In arm 3, Interleukin 2 is used for 12 weeks
Study NCT02360592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine
Description: In arm 3, Hepatitis B Vaccine is used for 48 weeks
Study NCT01374087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin 22.5 mg
Description: Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.
Study NCT01374087 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: Brachytherapy: Low or high dose rate.
Study NCT01374087 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Brachytherapy: Low or high dose rate.
Study NCT03809507 — intervention group
Intervention type: OTHER
Intervention: Qualtrics survey questions
Description: Qualtrics Survey:~For each of the scenarios, practitioners will be asked whether opioids are prescribed or not, and the type(s) of other analgesic medications that would be prescribed, the strength in mg, and the number of doses for each medication
Study NCT00206414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iressa Day 1 given with Arimidex and Faslodex
Description: timing of administration of iressa is the study factor
Study NCT00206414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iressa Day 21 given with Arimidex and Faslodex
Description: Timing of Iressa is the study factor
Study NCT04297137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein ingestion
Description: Ingestion of various sustainable non-animal derived protein sources compared to animal-based milk protein.
Study NCT04297137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein ingestion
Description: Ingestion of various sustainable non-animal derived protein sources compared to animal-based milk protein.
Study NCT03384550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-regulation coaching
Description: Short (2-5 min.) dialogue with the digital coach who provides information relevant for behavioral self-regulation, such as a goal reminder, the distance between the current step count and the goal and strategies to increase daily steps. Participants are randomized to self-regulation coaching or control (no coaching) on a daily basis.
Study NCT03384550 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-regulation coaching
Description: Short (2-5 min.) dialogue with the digital coach who provides information relevant for behavioral self-regulation, such as a goal reminder, the distance between the current step count and the goal and strategies to increase daily steps. Participants are randomized to self-regulation coaching or control (no coaching) on a daily basis.
Study NCT03384550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning
Description: A dialogue with the digital coach who prompts the participant to either formulate action plans (when and where the participant can go for a walk) or coping plans (strategies to respond to barriers for increasing daily steps) for the upcoming week. Participants are randomized on a weekly basis to action planning, coping planning or control (no planning).
Study NCT03384550 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Planning
Description: A dialogue with the digital coach who prompts the participant to either formulate action plans (when and where the participant can go for a walk) or coping plans (strategies to respond to barriers for increasing daily steps) for the upcoming week. Participants are randomized on a weekly basis to action planning, coping planning or control (no planning).
Study NCT03384550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Participants receive CHF 1 ($1) for each day they meet a personalized adaptive step goal.
Study NCT03384550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charity Incentives
Description: Participants donate CHF 1 ($1) to a charity of choice for each day they meet a personalized adaptive step goal.
Study NCT03475966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A kinesiologist will provide each patient wih an individualized home-based exercise program including aerobic, resistance and stretching exercises. Patients will also exercise at our clinic once per week under the supervision of the kinesiologist (prehabilitation arm only)
Study NCT03475966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: A kinesiologist will provide each patient wih an individualized home-based exercise program including aerobic, resistance and stretching exercises. Patients will also exercise at our clinic once per week under the supervision of the kinesiologist (prehabilitation arm only)
Study NCT03475966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Patients will be asked to fill in a 3-day food diary. A registered dietitian (RD) will review this diary, provide a full nutritional assessment, and ensure patients are following a high-protein diet (1.5 g of protein/kg/day). A whey-protein supplement may be provided to patients, should they require it. The RD will also ensure adequate calorie consumption for weight maintenance and will provided advice to help ease any GI issues the patients may be experiencing.
Study NCT04701580 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 11C-UCB-J PET-CT
Description: Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
Study NCT04701580 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 11C-UCB-J PET-CT
Description: Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
Study NCT04701580 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET-MR
Description: Positron Emission Tomography (PET) of glucose metabolism using the radioligand 18F-FDG, and brain MRI performed simultaneously.
Study NCT04701580 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG PET-MR
Description: Positron Emission Tomography (PET) of glucose metabolism using the radioligand 18F-FDG, and brain MRI performed simultaneously.
Study NCT02933840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlertWatch
Description: AlertWatch holds 510(k) FDA clearance K15335. It is a software program that takes data present in the medical record, including vital signs and laboratory results, and determines whether it meets predetermined thresholds for alerting a clinician. These thresholds are intended to correlate with signs of acute clinical deterioration in the patient being monitored.
Study NCT04143217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-812
Description: SPN-812 200 to 600 mg/day
Study NCT03225027 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positive And Negative Syndrome Scale
Description: Evaluating the clinical status of patients with schizophrenia.
Study NCT03225027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mini International Neuropsychiatric Interview
Description: Evaluating the exclusion criteria in healthy participants.
Study NCT03698786 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise
Description: Participants will be required to complete two, 8-hours trials (exercise \& control) in a randomised order, preceded by 2 hours of preliminary testing (baseline) with no more than 14 days between conditions.
Study NCT02428621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twicare® appliance
Description: Early orthodontic treatment with the Twicare®. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Twicare® is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night).
Study NCT02428621 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Removable Herbst appliance
Description: Early orthodontic treatment with the removable Herbst appliance. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Herbst appliance is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night).
Study NCT03209648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1450
Description: Debio 1450, 40 mg capsule.
Study NCT03209648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole, 20 mL of 10 mg/mL solution.
Study NCT03475966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition
Description: Patients will be asked to fill in a 3-day food diary. A registered dietitian (RD) will review this diary, provide a full nutritional assessment, and ensure patients are following a high-protein diet (1.5 g of protein/kg/day). A whey-protein supplement may be provided to patients, should they require it. The RD will also ensure adequate calorie consumption for weight maintenance and will provided advice to help ease any GI issues the patients may be experiencing.
Study NCT03475966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation techniques
Description: Patients will see a psychologist who will provide relaxation techniques (eg. imagery, visualization, deep breathing exercises) to help patients manage anxiety prior to surgery.
Study NCT03475966 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation techniques
Description: Patients will see a psychologist who will provide relaxation techniques (eg. imagery, visualization, deep breathing exercises) to help patients manage anxiety prior to surgery.